Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
2481-2500 of 3,900 trials

Sacituzumab Govitecan with Bevacizumab for Brain Metastases in Lung Cancer

We are studying a combination of two medications for patients with brain metastases from non-small cell lung cancer. The goal is to see how well this treatment works in reducing tumor size and improving patient outcomes.

Lung Cancer6-12 monthsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyOncology

PD-1 Antibody for Metastatic Solid Tumors

We are testing a new method of delivering a PD-1 antibody directly into the spinal fluid for patients with metastatic solid tumors and leptomeningeal disease. The study aims to determine the safe dosage and its potential impact on survival.

Leptomeningeal Disease6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesNeurologyOncology

Tacrolimus and Blood Sugar Control in Dialysis Patients

We are studying how tacrolimus affects blood sugar levels in patients on hemodialysis waiting for a kidney transplant. This research may help improve diabetes management in these patients.

Hemodialysis>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesEndocrinologyNephrology

Rotator Cuff Disease: Botulinum Toxin Treatment

We are studying whether botulinum toxin can help reduce pain and improve function in people with degenerative rotator cuff disease. Participants will be monitored for effectiveness and any side effects over three months.

Shoulder Tendonitis>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesOrthopedics and Traumatology

Chronic Lymphocytic Leukemia: Lisaftoclax and Acalabrutinib Study

We are testing a new drug combination for patients newly diagnosed with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. The study aims to see if this combination improves survival without disease progression compared to standard treatments.

Chronic Lymphocytic Leukemia (CLL) / Small Cell Lymphocytic Lymphoma (SLL)1-2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Advanced Melanoma: Regorafenib Treatment Study

We are studying the effects of regorafenib in patients with advanced melanoma who have already been treated. The goal is to see if it helps control the disease better when combined with other therapies.

Advanced Melanoma>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesDermatologyOncology

Melanoma Treatment: TILT-123 and Chemotherapy

We are studying a new oncolytic virus treatment combined with chemotherapy for patients with melanoma. This trial aims to see if this combination can improve treatment outcomes.

Melanoma>2 yearsSafety phase (I)DermatologyOncology

Extra-Mammary Paget's Disease: PAGETEX Device Study

We are studying the PAGETEX device to see if it helps control Extra-Mammary Paget's Disease of the vulva. The trial will also look at pain levels, quality of life, and patient satisfaction during treatment.

Paget's Disease of the Vulva6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Intracerebral Hemorrhage: Anticoagulation Strategies

We are studying whether avoiding anticoagulation or using a specific procedure helps improve health outcomes for patients after an intracerebral hemorrhage. We also aim to identify brain markers that may indicate future bleeding risks.

Cerebral Hemorrhage1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineNeurology

Caffeine Treatment for Early Alzheimer's Disease

We are studying whether a 30-week caffeine treatment can help improve thinking and memory in people with early to moderate Alzheimer's disease. This trial compares the effects of caffeine to a placebo to see if it makes a difference.

Alzheimer's Disease6-12 monthsConfirmation phase (III)Investigational MedicinesPartially RemoteNeurology

Multiple Myeloma: Teclistamab with Daratumumab or Lenalidomide

We are studying the effectiveness and safety of a new treatment combination for elderly patients with newly diagnosed multiple myeloma. This research aims to find better ways to manage the disease.

Multiple Myeloma>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHematologyOncology

Malignant Pleural Mesothelioma: Innovative Treatment Study

We are exploring a new treatment combining light therapy and immunotherapy for patients with malignant pleural mesothelioma. The study aims to assess safety, effectiveness, and impact on quality of life.

Malignant Pleural Mesothelioma>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesOncologyPulmonology

Mesothelioma: Talazoparib Maintenance Treatment

We are studying whether talazoparib can help keep mesothelioma from progressing after initial chemotherapy. This trial is for patients with advanced pleural or peritoneal mesothelioma.

Advanced Malignant Mesothelioma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Heart Failure: Vericiguat Study

We are studying the effects of vericiguat in patients with heart failure and reduced ejection fraction. The goal is to see if it can lower heart failure markers compared to a placebo.

Heart Failure with Reduced Ejection Fraction (HFrEF)3-6 monthsMonitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Atrial Fibrillation: Amiodarone Dose Comparison

We are studying whether a standard or reduced dose of amiodarone is more effective in keeping a normal heart rhythm after cardioversion in patients with persistent atrial fibrillation. We will also assess any side effects and how genetics may affect treatment.

Persistent Atrial Fibrillation>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCardiologyInternal Medicine

Hemorrhoidal Disease: RAFAELO® Procedure with Pain Management

We are studying whether adding perianal infiltration during the RAFAELO® procedure helps reduce pain after treatment for hemorrhoids. This trial aims to improve comfort for patients undergoing this procedure.

Hemorrhoids>2 yearsConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

Ginisortamab for Advanced Pancreatic Cancer

We are studying the safety and effectiveness of ginisortamab combined with standard treatments for metastatic pancreatic cancer. This trial will help us understand how well it works and its potential side effects.

Metastatic Pancreatic Cancer1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesGastroenterologyOncology

Immunoglobulin A Nephropathy: Povetacicept Study

We are evaluating a new treatment for adults with Immunoglobulin A Nephropathy to see if it helps reduce protein in urine and preserve kidney function. The study also looks at its effects on slowing kidney failure and improving fatigue.

Immunoglobulin A Nephropathy>2 yearsConfirmation phase (III)>20 visitsInvestigational MedicinesCost ReimbursementNephrology

Non-Small Cell Lung Cancer: 68GaNOTA-Anti-MMR Imaging Study

We are testing a new imaging agent to see how well it can identify certain immune cells in patients with non-small cell lung cancer. This may help improve imaging techniques for better diagnosis and treatment planning.

Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncologyOtolaryngologyPulmonology

Multiple Myeloma: Elranatamab Combination Therapy

We are studying a new treatment combination for patients with newly diagnosed multiple myeloma who cannot have a transplant. The goal is to see if it works better than a standard treatment option.

Multiple Myeloma>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology